KZIA Projected Dividend Yield
ADR (Sponsored)/Kazia Therapeutics Ltd ( NASDAQ : KZIA )Kazia Therapeutics is an oncology-focused biotechnology company that has a portfolio of development candidates in a range of oncology indications. Co.'s primary development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase/Akt/mTor pathway, that is being developed as a potential therapy for glioblastoma as well as other forms of brain cancer. Paxalisib is orally administered and is presented in a 15mg capsule formulation. Co.'s second development candidate is EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. EVT801 selectively targets lymphangiogenesis, the formation of new lymphatic vessels. 20 YEAR PERFORMANCE RESULTS |
KZIA Dividend History Detail KZIA Dividend News KZIA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |